Cellectar Begins New CLR 131 Trial
Cellectar Biosciences has started a trial for CLR 131 in Waldenstrom’s macroglobulinemia (WM), the company announced recently. According to a release, the trial will include 50 WM patients who will…
Tag Archives: Cellectar Biosciences
Cellectar Prices Underwritten Public Offering
Cellectar Biosciences announced today the pricing of its underwritten public offering of its common stock at $1.35 per share, which will result in gross proceeds of approximately $24.5 million. Cellectar also…
Cellectar Announces $20M Public Offering
Cellectar Biosciences today announced the effective prices of $1.15 per share of common stock and one-half of a Series H Warrant of an underwritten public offering to raise approximately $20…
Cellectar Awarded European Patent
Cellectar Biosciences announced today that it has received a European patent for the composition of matter and use protection for the treatment and/or diagnosis of cancer and cancer stem cells for…
Sixth Orphan Drug Designation Granted to Cellectar
Cellectar Biosciences has been granted orphan drug designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL) by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development, the company…
Cellectar Biosciences Receives $10M
Cellectar Biosciences announced today it has entered into definitive agreements with institutional investors to purchase approximately $5 million in a registered direct offering of 1,982,000 common shares and approximately $5…
Cellectar’s CLR 131 Granted Japanese Patent
Cellectar Biosciences has received a patent for CLR 131 by the Japan Patent Office, the company announced recently. “Certain cancers such as pediatric lymphomas and leukemias have a higher prevalence…
Cellectar’s CLR 131 Receives Fourth RPDD
Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of osteosarcoma, the company announced recently. “Cellectar is pleased to have the opportunity to…
Cellectar’s CLR 131 Receives RPDD
Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of Ewing’s sarcoma, a rare pediatric cancer, by The U.S. Food and Drug Administration…
Cellectar Closes $16.56M Public Offering
Cellectar Biosciences today announced the effective prices of $4.00 per share of common stock of an underwritten public offering to raise approximately $16.56 million. According to a release, this includes the full…
